268 related articles for article (PubMed ID: 27931982)
1. JAK-inhibitor tofacitinib suppresses interferon alfa production by plasmacytoid dendritic cells and inhibits arthrogenic and antiviral effects of interferon alfa.
Boor PPC; de Ruiter PE; Asmawidjaja PS; Lubberts E; van der Laan LJW; Kwekkeboom J
Transl Res; 2017 Oct; 188():67-79. PubMed ID: 27931982
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 Infection Induces Psoriatic Arthritis Flares and Enthesis Resident Plasmacytoid Dendritic Cell Type-1 Interferon Inhibition by JAK Antagonism Offer Novel Spondyloarthritis Pathogenesis Insights.
Zhou Q; Vadakekolathu J; Watad A; Sharif K; Russell T; Rowe H; Khan A; Millner PA; Loughenbury P; Rao A; Dunsmuir R; Timothy J; Damiani G; Pigatto PDM; Malagoli P; Banfi G; El-Sherbiny YM; Bridgewood C; McGonagle D
Front Immunol; 2021; 12():635018. PubMed ID: 33936047
[TBL] [Abstract][Full Text] [Related]
3. Bcl-2 antagonists kill plasmacytoid dendritic cells from lupus-prone mice and dampen interferon-α production.
Zhan Y; Carrington EM; Ko HJ; Vikstrom IB; Oon S; Zhang JG; Vremec D; Brady JL; Bouillet P; Wu L; Huang DC; Wicks IP; Morand EF; Strasser A; Lew AM
Arthritis Rheumatol; 2015 Mar; 67(3):797-808. PubMed ID: 25418983
[TBL] [Abstract][Full Text] [Related]
4. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells.
Kubo S; Yamaoka K; Kondo M; Yamagata K; Zhao J; Iwata S; Tanaka Y
Ann Rheum Dis; 2014 Dec; 73(12):2192-8. PubMed ID: 24013646
[TBL] [Abstract][Full Text] [Related]
5. Sitagliptin and tofacitinib ameliorate adjuvant induced arthritis via modulating the cross talk between JAK/STAT and TLR-4/NF-κB signaling pathways.
Ibrahim SSA; Salama MA; Selima E; Shehata RR
Life Sci; 2020 Nov; 260():118261. PubMed ID: 32795539
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.
Zhang H; Watanabe R; Berry GJ; Tian L; Goronzy JJ; Weyand CM
Circulation; 2018 May; 137(18):1934-1948. PubMed ID: 29254929
[TBL] [Abstract][Full Text] [Related]
7. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
Boyle DL; Soma K; Hodge J; Kavanaugh A; Mandel D; Mease P; Shurmur R; Singhal AK; Wei N; Rosengren S; Kaplan I; Krishnaswami S; Luo Z; Bradley J; Firestein GS
Ann Rheum Dis; 2015 Jun; 74(6):1311-6. PubMed ID: 25398374
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors.
Gao W; McGarry T; Orr C; McCormick J; Veale DJ; Fearon U
Ann Rheum Dis; 2016 Jan; 75(1):311-5. PubMed ID: 26353790
[TBL] [Abstract][Full Text] [Related]
9. Tofacitinib Represses the Janus Kinase-Signal Transducer and Activators of Transcription Signalling Pathway in Keratinocytes.
Srivastava A; Ståhle M; Pivarcsi A; Sonkoly E
Acta Derm Venereol; 2018 Aug; 98(8):772-775. PubMed ID: 29738047
[TBL] [Abstract][Full Text] [Related]
10. IgG-derived Fc down-regulates virus-induced plasmacytoid dendritic cell (pDC) IFNalpha production.
Green DS; Lum T; Green JA
Cytokine; 2004 Jun; 26(5):209-16. PubMed ID: 15157898
[TBL] [Abstract][Full Text] [Related]
11. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.
Tanaka Y; Yamaoka K
Mod Rheumatol; 2013 May; 23(3):415-24. PubMed ID: 23212593
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.
Tanaka Y; Maeshima K; Yamaoka K
Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i70-4. PubMed ID: 22460142
[TBL] [Abstract][Full Text] [Related]
13. The Janus kinase inhibitor tofacitinib inhibits TNF-α-induced gliostatin expression in rheumatoid fibroblast-like synoviocytes.
Kawaguchi Y; Waguri-Nagaya Y; Tatematsu N; Oguri Y; Kobayashi M; Nozaki M; Asai K; Aoyama M; Otsuka T
Clin Exp Rheumatol; 2018; 36(4):559-567. PubMed ID: 29352846
[TBL] [Abstract][Full Text] [Related]
14. Effect of
Gardet A; Pellerin A; McCarl CA; Diwanji R; Wang W; Donaldson D; Franchimont N; Werth VP; Rabah D
Front Immunol; 2019; 10():275. PubMed ID: 30846987
[No Abstract] [Full Text] [Related]
15. Tofacitinib attenuates arthritis manifestations and reduces the pathogenic CD4 T cells in adjuvant arthritis rats.
Gertel S; Mahagna H; Karmon G; Watad A; Amital H
Clin Immunol; 2017 Nov; 184():77-81. PubMed ID: 28461107
[TBL] [Abstract][Full Text] [Related]
16. Rotavirus structural proteins and dsRNA are required for the human primary plasmacytoid dendritic cell IFNalpha response.
Deal EM; Jaimes MC; Crawford SE; Estes MK; Greenberg HB
PLoS Pathog; 2010 Jun; 6(6):e1000931. PubMed ID: 20532161
[TBL] [Abstract][Full Text] [Related]
17. Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells.
Ando S; Kawada JI; Watanabe T; Suzuki M; Sato Y; Torii Y; Asai M; Goshima F; Murata T; Shimizu N; Ito Y; Kimura H
Oncotarget; 2016 Nov; 7(47):76793-76805. PubMed ID: 27732937
[TBL] [Abstract][Full Text] [Related]
18. C1q inhibits immune complex-induced interferon-alpha production in plasmacytoid dendritic cells: a novel link between C1q deficiency and systemic lupus erythematosus pathogenesis.
Lood C; Gullstrand B; Truedsson L; Olin AI; Alm GV; Rönnblom L; Sturfelt G; Eloranta ML; Bengtsson AA
Arthritis Rheum; 2009 Oct; 60(10):3081-90. PubMed ID: 19790049
[TBL] [Abstract][Full Text] [Related]
19. Tofacitinib for the treatment of moderate-to-severe psoriasis.
Chiricozzi A; Faleri S; Saraceno R; Bianchi L; Buonomo O; Chimenti S; Chimenti MS
Expert Rev Clin Immunol; 2015 Apr; 11(4):443-55. PubMed ID: 25666451
[TBL] [Abstract][Full Text] [Related]
20. Cellular and functional actions of tofacitinib related to the pathophysiology of hibernoma development.
Radi ZA; Vogel WM; Bartholomew PM; Koza-Taylor P; Papanikolaou A; Wisialowski T; Nambiar P; Ball DJ
Regul Toxicol Pharmacol; 2017 Dec; 91():93-102. PubMed ID: 29074274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
